MedPath

Effects of Exogenous Ketone Ester Supplementation on 3-hydroxybutyrate Concentrations in Human Cerebrospinal Fluid

Not Applicable
Recruiting
Conditions
Ketosis
Interventions
Dietary Supplement: Ketone Ester
Other: Placebo
Registration Number
NCT06318299
Lead Sponsor
University of Aarhus
Brief Summary

It is well established that the brain is capable of consuming ketone bodies, especially during low glucose availability, e.g. fasting. Cerebral metabolism of ketone bodies depends on passage of the blood brain barrier and especially the global blood concentration of ketone bodies.

Ketone bodies can be administered exogenously, and the most commonly used in clinical trials is 3-hydroxybutyrate (3-OHB). 3-OHB is carried by simple diffusion and facilitated diffusion through several monocarboxylic acid transporters (MCTs) across the blood-brain barrier.

To our knowledge, no studies in human adults exist that concurrently measure 3-OHB concentrations in blood and cerebrospinal fluid (CSF) after ingestion or infusion of exogenous ketone supplementation, necessitating further study.

Aims:

* The 3-OHB CSF/blood ratio after oral ingestion of 30 g ketone ester - primary endpoint

* The window of effect: Ketone supplementation 1 h or 2 h before CSF sampling

* If concentration measurements by point-of-care testing are non-inferior to mass spectrometry

* If acute 3-OHB ingestion increases plasma brain-derived neurotrophic factor (BDNF) levels

Detailed Description

Not available

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
24
Inclusion Criteria
  • All sexes
  • Referred to undergo an elective lumbar puncture procedure in the outpatient clinic at Department of Neurology, Aarhus University Hospital.
  • Age 18-80 years
  • Written and oral consent
Read More
Exclusion Criteria
  • Referred to the clinic suspecting severe neuroinflammation
  • Special diet habits, including ketogenic diet, fasting, intermittent fasting etc.
  • Daily use of insulin or other medication affecting blood glucose and/or glucose metabolism
  • Not able to speak or understand Danish and/or give written and oral consent
Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Ketone 2 hoursKetone EsterKetone ester drink administered two hours before elective lumbar puncture
Ketone 1 hourKetone EsterKetone ester drink administered one hour before elective lumbar puncture
Placebo 1 hourPlaceboPlacebo drink administered one hour before elective lumbar puncture
Primary Outcome Measures
NameTimeMethod
3-OHB CSF/blood ratio1-2 hours after ingestion

After oral ingestion of 30 g ketone ester drink or placebo drink

Secondary Outcome Measures
NameTimeMethod
Plasma BDNF concentrationsBefore ingestion

Before oral ingestion of 30 g ketone ester drink or placebo drink

CSF 3-OHB concentrations, POCT1-2 hours after ingestion

After oral ingestion of 30 g ketone ester drink or placebo drink, Point-of-care testing (POCT)

Blood 3-OHB concentrationsBefore ingestion

Before oral ingestion of 30 g ketone ester drink or placebo drink, Point-of-care testing (POCT)

Plasma 3-OHB concentrationsBefore ingestion

After oral ingestion of 30 g ketone ester drink or placebo drink, Mass Spectrometry Detection

CSF glucose concentrations1-2 hours after ingestion

After oral ingestion of 30 g ketone ester drink or placebo drink

CSF 3-OHB concentrations, Mass Spectrometry1-2 hours after ingestion

After oral ingestion of 30 g ketone ester drink or placebo drink, Mass Spectrometry Detection

Blood glucose concentrationsBefore ingestion

Before oral ingestion of 30 g ketone ester drink or placebo drink, Point-of-care testing (POCT)

Trial Locations

Locations (1)

Aarhus University Hospital

🇩🇰

Aarhus, Denmark

© Copyright 2025. All Rights Reserved by MedPath